Monoclonal Antibodies to Gangliosides Raised in Ganglioside-Deficient Knockout Mice

Knock-out mice lacking complex gangliosides were found to be improved hosts for raising high affinity, high titer monoclonal IgG anti-ganglioside antibodies. Gangliosides are major cell surface determinants in the vertebrate nervous system. Although their functions have not been fully defined, gangliosides are thought to mediate neural cell-cell recognition and modulate intracellular signaling. Anti-ganglioside antibodies have also been implicated in autoimmune neuropathies and have been proposed as selective anti-cancer agents. Hybridoma Cell Lines are now available for producing the following monoclonal antibodies: Hybridoma IgG Class Ganglioside Specificity (1) IgG1 GD1a (2) IgG2a GD1a (3) IgG2b GD1a (4) IgG1 GT1b (5) IgG2a GT1b (6) IgG2b GT1b (7) IgG1 GM1 (8) IgG2b cross reactive:GD1a/GT1b/GT1aa Additional IgG-class anti-ganglioside antibodies to GM1 (IgG2a, IgG2b) and GD1b (IgG1,IgG2a, IgG2b) are anticipated in 3-6 months. Description (Set) Proposed Use (Set) The above high titer IgG antibodies present valuable research tools for not only the study of ganglioside physiological functions but for assessing the pathogenic significance of anti-ganglioside antibodies in neurological disorders. Ganglioside biology is increasingly relevant to the pathogenesis of neurological disorders as the conditions associated with antibodies against complex gangliosides increase in number. For example, IgG anti-GQ1b and IgG anti-GD1a antibodies are implicated in the pathogenesis of Fisher Syndrome and the motor-axonal variant of Guillain-Barre Syndrome respectively.

Inventor(s): Lunn, Michael P.T.

Type of Offer: Licensing



« More Medical Patents

---